3-(2,2,2-trimethylhydrazine)propionate has been researched along with Diabetes Mellitus, Type 2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fabritskaya, SV; Shilina, NN; Statsenko, S; Turkin, SV | 1 |
| Apukhtin, AF; Dudchenko, GP; Poletaeva, LV; Statsenko, ME; Turkina, SV | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L | 1 |
| Belenkova, SV; Shilina, NN; Sporova, OE; Statsenko, ME | 1 |
2 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Mildronate effects on oxidant stress in type 2 diabetic patients with diabetic peripheral (sensomotor) neuropathy].
Topics: Aged; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fasting; Female; Humans; Male; Methylhydrazines; Middle Aged; Oxidative Stress | 2008 |
[The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus].
Topics: Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies | 2007 |
2 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Efficacy of Short-Term Therapy With Meldonium in Patients With Chronic Heart Failure of Ischemic Etiology and Type 2 Diabetes Mellitus].
Topics: Aged; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 2017 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructosamine; Heart; Hyperalgesia; Hypoglycemic Agents; In Vitro Techniques; Lipids; Male; Methylhydrazines; Myocardial Ischemia; Pain Threshold; Rats; Rats, Wistar | 2009 |